Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market Size, Share & Industry Trends Analysis Report By Therapy (Mono Drug Therapy and Combination Drug Therapy), By Therapeutics Class, By Country and Growth Forecast, 2021-2027

The Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market is expected to witness market growth of 6.5% CAGR during the forecast period (2021-2027).

In the male reproductive system, the prostate is a walnut-sized gland that surrounds the urethra. This gland's major job is to emit a fluid that combines with the fluids from other glands and sperm cells from the testicles to form semen. BPH (benign prostatic hyperplasia) is a non-cancerous enlargement of the prostate gland. This causes increased frequency of urination at night which is majorly called nocturia, urinary hesitancy, and urinary retention because the urine flow from the bladder is blocked.

Because of symptoms like urine leakage, BPH has a substantial impact on the patient's quality of life. It can lead to more significant health problems, such as bladder damage, bladder stones, kidney damage, and urinary tract infections, if left untreated for a long time (UTIs).

However, the incidence of BPH in mainland China did not show a consistent trend, and a prevalence map centered on a geographic information system (GIS) revealed an unequal regional distribution. Further, due to the increased population of the country, more people are likely to attain BHP. This factor is expected to further accelerate the demand for the benign prostatic hyperplasia therapeutics in the region.

The China market dominated the Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $786.3 million by 2027. The Japan market is poised to grow a CAGR of 5.9% during (2021 - 2027). Additionally, The India market is expected to showcase a CAGR of 7.5% during (2021 - 2027).

Based on Therapy, the market is segmented into Mono Drug Therapy and Combination Drug Therapy. Based on Therapeutics Class, the market is segmented into Alpha Blockers, 5- alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Astellas Pharma, Inc., Eli Lilly and Company, Allergan PLC (AbbVie), Merck Group (Merck Sharp & Dohme Corp.), Boehringer Ingelheim International GmbH, Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Pfizer, Inc., and Abbott Laboratories.

Scope of the Study

Market Segments Covered in the Report:

By Therapy

• Mono Drug Therapy
• Combination Drug Therapy

By Therapeutics Class

• Alpha Blockers
• 5- alpha Reductase Inhibitors
• Phosphodiesterase-5 Inhibitors
• Others

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

• GlaxoSmithKline PLC (GSK)
• Astellas Pharma, Inc.
• Eli Lilly and Company
• Allergan PLC (AbbVie)
• Merck Group (Merck Sharp & Dohme Corp.)
• Boehringer Ingelheim International GmbH
• Teva Pharmaceuticals Industries Ltd.
• Sanofi S.A.
• Pfizer, Inc.
• Abbott Laboratories

Unique Offerings from the Publisher

• Exhaustive coverage
• The highest number of market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free